Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV in Pediatric Active Chronic Pouchitis
2023-504773-20-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of vedolizumab in pouchitis, sponsored by Takeda. Primary endpoint: Primary clinical remission at Week 14. Planned start Jun 2024; status: authorised.
02
Drugs
vedolizumab
03
Conditions
pouchitis
Beyond the preview
Go deeper on 2023-504773-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504773-20-00.